about
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to addr...
Read More
27.38
0.83
(3.13%)
1.3M
XNAS Volume
XNAS 15 Apr, 2026 3:58 PM (EDT)
Not Eligible
Expensive Valuation
Technically Moderately Bullish
Immunovant Inc Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..